Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Metamizole Sodium, also widely known as Dipyrone or Novalgin, is a potent non-opioid analgesic and antipyretic agent belonging to the pyrazolone class of drugs. Its chemical formula is C13H16N3NaO4S, and it is identified by the CAS Registry Number 5908-72-5. This compound functions primarily by inhibiting cyclooxygenase enzymes, thereby reducing the production of prostaglandins that mediate pain and fever. Unlike many other analgesics, Metamizole possesses strong spasmolytic properties, making it particularly effective for treating visceral colic, such as renal or biliary pain, where smooth muscle relaxation is beneficial.
The drug is extensively used in over forty countries across Europe, Latin America, Asia, and Africa, though its availability varies significantly due to safety concerns. In nations like Germany, Spain, and Mexico, it remains a first-line treatment for severe acute pain, often reserved for cases where NSAIDs or opioids are contraindicated or ineffective. It is frequently administered intravenously or intramuscularly in hospital settings for rapid relief of high-grade fevers and post-operative pain. Despite its efficacy, Metamizole has been banned or restricted in several Western countries, including the United States and the United Kingdom, primarily due to the rare but serious risk of agranulocytosis, a potentially life-threatening condition characterized by a severe drop in white blood cell count.
Clinical guidelines emphasize strict patient monitoring when using this medication to mitigate hematological risks. While newer alternatives exist, Metamizole continues to hold a critical role in global pharmacotherapy for specific indications requiring powerful analgesia without respiratory depression. Its unique mechanism and broad spectrum of activity ensure its persistence in medical formularies worldwide, balancing therapeutic benefits against potential adverse events through careful clinical oversight. As research continues, the focus remains on optimizing dosage protocols and identifying safer patient populations to maximize its utility while minimizing rare complications.